Get the Stockscreener App
4.83
3.40%
-0.17
Pre-market:
4.83
Pavmed Inc stock is traded at $4.83, with a volume of 7,787.
It is down -3.40% in the last 24 hours and down -26.03% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$5.00
Open:
$5
24h Volume:
7,787
Relative Volume:
0.54
Market Cap:
$34.58M
Revenue:
$71,000
Net Income/Loss:
$-2.47M
P/E Ratio:
-0.1467
EPS:
-32.9143
Net Cash Flow:
$-5.24M
1W Performance:
-6.76%
1M Performance:
-26.03%
6M Performance:
-48.48%
1Y Performance:
-74.78%
1-Day Range:
$4.825
$5.00
1-Week Range:
$4.50
$5.41
52-Week Range:
$4.50
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
4.83 | 34.58M | 71,000 | -2.47M | -5.24M | -32.91 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVM Maintains Buy Rating -- Price Target Lowered to $56.00 by A - GuruFocus
PAVmed Inc (PAVM) Stock Price & 30 Year Financial Data - GuruFocus
PAVM Technical Analysis | Trend, Signals & Chart Patterns | PAVMED INC (NASDAQ:PAVM) - ChartMill
How The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price Target - Yahoo Finance
PAVM assigns Joseph Virgilio to lead medical device portfolio relaunch - MSN
PAVmed Q1 2026 earnings preview - MSN
PAVM Q1 2026 Earnings: Massive EPS Miss Deepens Concerns as Revenue Remains Nonexistent - thelegaladvocate.com
LUCD - Finviz
PAVM Technical Analysis & Stock Price Forecast - Intellectia AI
PAVmed Inc. (PAVM) Gains 2.44% as Stock Tests Key Resistance Near $6.62Size Factor - newsline.com
PAVmed Inc. (PAVM) reports Q1 loss, lags revenue estimates - MSN
PAVM PE Ratio & Valuation, Is PAVM Overvalued - Intellectia AI
Will PAVmed Inc. (PAVM) report negative earnings next week? What you should know - MSN
PAVM|PAVmed Inc|Price:6.390|Chg%:0.04 - TradingKey
Earnings call transcript: PAVmed Q1 2026 sees restructuring gains By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed Q1 2026 sees restructuring gains - Investing.com India
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-05-19 - Seeking Alpha
PAVmed Inc earnings dates,PAVmed Inc earnings estimates - RTTNews
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc. (NASDAQ:PAVM) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Re - GuruFocus
PAVM Reports Strong Q1 Growth and Financial Position - GuruFocus
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Two Seas Capital (NASDAQ: PAVM) Holds 9.99% of PAVmed, Including Warrants - Stock Titan
PAVM: Restructuring completed; subsidiaries near major milestones and capital structure is simplified - TradingView
PAVmed Inc.Common Stock (NQ: PAVM - FinancialContent
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed Releases Q1 2026 Financial Results - AlphaStreet
PAVmed targets Varis FDA submission by end of 2026 while evaluating new assets following cap table cleanup - MSN
PAVmed Q1 2026 Earnings Call Insights - Intellectia AI
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
PAVmed Q1 2026 Earnings Call Transcript - Benzinga
PAVM: Restructuring complete; subsidiaries advancing, with growth tied to capital and milestone achievements - TradingView
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
PAVM: Restructuring enables growth, with Lucid and Veris advancing toward major milestones - TradingView
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains - Investing.com
PAVmed (PAVM) Q1 2026: EPS $(4.42) Misses $(0.70) Estimate; Reve - GuruFocus
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
PAVmed Reports Q1 2026 Results and Business Update - TipRanks
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):